Do you qualify for a GLP-1 if you have prediabetes but not diabetes?

Dr. Linda's take

This question sounds like it should have a yes or no answer. It does not, because it carries a hidden assumption worth pulling apart.

Prediabetes is a real diagnosis with real consequences. But it is not, by itself, a reason any medication in this class is approved. So when someone with prediabetes asks whether they qualify, the honest answer is that prediabetes is not the door. It may be part of what gets you through a different door, the one built for chronic weight management, and it may not be, depending on the rest of your picture.

What follows is how that door actually works, because the criteria are more specific than most articles suggest, and because they are less numeric than you have probably been told. This is general education, not a recommendation for any individual, and nothing here can tell you whether you qualify. Only a clinician who knows your full history can do that.

What is prediabetes, exactly?

Prediabetes describes blood glucose that sits above the normal range but below the threshold for a type 2 diabetes diagnosis. It is a marker on a continuum rather than a separate disease, which is part of why so many people find out almost by accident, from a routine lab draw ordered for something else.

It is not a holding pattern, either. Without intervention it tends to move in one direction: people with prediabetes have a high chance of developing type 2 diabetes within 5 to 10 years.

Whether these medications change prediabetes itself is a separate question with a genuinely surprising answer, and we cover it in our companion piece on reversing prediabetes. This article stays on the narrower question of qualification.

Why is prediabetes not, on its own, an approved reason?

Because it is not on the label. We read the current prescribing information for Wegovy and for Zepbound, and neither one carries an indication for prediabetes.

Wegovy's approved uses are to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity or in adults with overweight in the presence of at least one weight-related comorbid condition, and for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis.

Zepbound's approved uses are to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.

Read both lists again and notice what is absent. There is no prediabetes indication, and no diabetes-prevention indication either. Qualification therefore runs entirely through the chronic weight management criteria, which is a different question from the one most people think they are asking.

How do the label criteria actually work?

Here is the part that surprises people, including clinicians who have not reread the label lately.

The indication itself no longer turns on a BMI number. Both labels describe the eligible population in words rather than numbers: obesity, or overweight plus at least one weight-related comorbid condition.

The numbers you have heard are still real, and they are still the working definitions. They simply live somewhere else on the document. In the clinical studies sections, the trials that supported these approvals enrolled adults with obesity, defined as BMI greater than or equal to 30 kg/m2, or with overweight, defined as BMI 27 to 29.9 kg/m2 on the Wegovy label and BMI 27 to less than 30 kg/m2 on the Zepbound label, plus at least one weight-related comorbid condition.

So the practical shape is the one you have heard: roughly BMI 30 and above on its own, or roughly BMI 27 and above with a qualifying condition alongside it. What changed is where that lives and how rigid it is. The label states the shape; the trials state the numbers the shape was built on. For a fuller walkthrough of the whole screening picture, including the histories that rule people out, see our eligibility checklist.

Does prediabetes count as a weight-related comorbid condition?

This is the crux, and the honest answer is that the label does not say.

Both labels give examples of what a weight-related comorbid condition looks like, and both lists are illustrative rather than exhaustive. The Wegovy label's trials enrolled people with at least one weight-related comorbid condition such as treated or untreated dyslipidemia or hypertension. The Zepbound label's trials enrolled people with at least one weight-related comorbid condition such as dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease.

Neither list names prediabetes. We searched the full current prescribing information for both products, and the word prediabetes does not appear anywhere in the Wegovy label, while on the Zepbound label it appears only once, as a baseline characteristic of participants in the sleep apnea trials rather than as a qualifying condition.

That leaves prediabetes in a real but unofficial position. It is a weight-related metabolic condition by any clinical reading, and testing for it is recommended for adults who have overweight or obesity along with other risk factors. But because the label's examples are illustrative, prediabetes is neither included nor excluded by name. Whether it is documented as the qualifying comorbid condition is a clinical judgment rather than something the label settles.

That is worth knowing before you walk in. It means two reasonable clinicians can look at the same chart and land differently, and it means the phrasing in your notes matters more than most people realize.

Why is being eligible not the same as being covered?

These are two different decisions, made by two different parties, using two different rulebooks.

The label is the FDA's statement about who a medication is approved for. Coverage is a payer's statement about what it is willing to pay for, and payers routinely layer their own criteria on top of the label.

Medicare is the clearest illustration. CMS lists "agents when used for anorexia, weight loss, or weight gain" among the product categories excluded from the definition of a covered Part D drug. So a person can meet every clinical criterion exactly and still receive a coverage answer that has nothing to do with clinical eligibility.

Coverage policy also moves far faster than the label does, and self-pay changes the calculus for some people entirely. Rather than repeat any of it here, our maintained guides go deeper: see the 2026 insurance coverage guide and the guide to getting covered through a comorbidity.

The relief in this distinction is that a coverage denial is not a verdict on your body. It is a verdict on a policy document.

What should you ask your clinician?

If you want a structured way into that conversation, Body Good Studio's quiz maps your symptoms to a starting point before you speak with a clinician.

Frequently asked questions

Does prediabetes alone qualify you?

No. Prediabetes is not an approved indication on any current label in this class, so it cannot be the basis for qualification on its own. Qualification runs through the chronic weight management criteria instead, where prediabetes may or may not be counted as the weight-related comorbid condition alongside a BMI in the overweight range.

What BMI do you need?

The current Wegovy and Zepbound labels state the indication in words, obesity or overweight with at least one weight-related comorbid condition, rather than as a numeric cutoff. The trials behind those approvals enrolled adults with obesity, defined as BMI greater than or equal to 30 kg/m2, or with overweight, defined as BMI 27 to 29.9 kg/m2 on the Wegovy label and BMI 27 to less than 30 kg/m2 on the Zepbound label.

Is prediabetes listed as a weight-related comorbid condition?

Not by name. The examples given on these labels are conditions such as treated or untreated dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease. Because those lists are illustrative rather than exhaustive, prediabetes is neither included nor excluded, which is exactly why it becomes a clinician's judgment call.

If you qualify clinically, will a plan pay?

Not necessarily, and the two questions are genuinely separate. CMS lists agents used for weight loss among the categories excluded from the definition of a covered Part D drug, and commercial plans set their own criteria on top of the label. Meeting the clinical criteria is a starting point for that conversation, not a guarantee of it.

Why does the distinction between the label and prediabetes matter so much?

Because it changes what you are actually asking for, and therefore how the conversation goes. Asking whether prediabetes qualifies you invites a no. Asking how your full picture, prediabetes included, maps onto the chronic weight management criteria is a question a clinician can actually work with.

References

1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2026). Prediabetes & Insulin Resistance. National Institutes of Health. https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance (Accessed 2026-07-16).
2. Novo Nordisk / U.S. Food and Drug Administration (2026). WEGOVY (semaglutide) injection, solution; WEGOVY (semaglutide) tablet - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-16).
3. Eli Lilly and Company / U.S. Food and Drug Administration (2026). ZEPBOUND (tirzepatide) injection, solution - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-16).
4. Centers for Medicare & Medicaid Services (2026). Part D Drugs / Part D Excluded Drugs. Centers for Medicare & Medicaid Services. https://www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovcontra/downloads/partddrugspartdexcludeddrugs.pdf (Accessed 2026-07-16).